Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m².

Autor: O'Kane, Cavan P.¹ (AUTHOR) Cavan.OKane.m@wvumedicine.org, Avalon, Juan Carlo O.² (AUTHOR), Lacoste, Jordan L.¹ (AUTHOR), Fang, Wei³ (AUTHOR), Bianco, Christopher M.⁴ (AUTHOR), Davisson, Laura^2,5 (AUTHOR), Piechowski, Kara L.¹ (AUTHOR)

Publikováno v: Pharmacotherapy. Feb2022, Vol. 42 Issue 2, p112-118. 7p.

Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m ² .

Autor: O'Kane CP; Department of Pharmacy, WVU Medicine, Morgantown, West Virginia, USA., Avalon JCO; Department of Internal Medicine, West Virginia University School of Medicine, Morgantown, West Virginia, USA., Lacoste JL; Department of Pharmacy, WVU Medicine, Morgantown, West Virginia, USA., Fang W; West Virginia Clinical and Translational Science Institute, Morgantown, West Virginia, USA., Bianco CM; Department of Cardiovascular and Thoracic Surgery, WVU Medicine, Morgantown, West Virginia, USA., Davisson L; Department of Internal Medicine, West Virginia University School of Medicine, Morgantown, West Virginia, USA.; WVU Medicine Medical and Surgical Weight Loss Center's Medical Weight Management Program, Morgantown, West Virginia, USA., Piechowski KL; Department of Pharmacy, WVU Medicine, Morgantown, West Virginia, USA.

Publikováno v: Pharmacotherapy [Pharmacotherapy] 2022 Feb; Vol. 42 (2), pp. 112-118. Date of Electronic Publication: 2021 Dec 09.